New vaccine aims to shield older adults from pneumonia
NCT ID NCT07105722
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests a new vaccine called Pn-MAPS30plus that may protect against more types of pneumonia bacteria than current vaccines. It involves 127 healthy adults aged 50 to 64. The main goal is to check if the vaccine is safe and helps the body build a strong immune defense.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA - BACTERIAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Norwood, South Australia, 5067, Australia
-
GSK Investigational Site
Bayswater, Victoria, 3153, Australia
-
GSK Investigational Site
Camberwell, Victoria, 3124, Australia
-
GSK Investigational Site
East Melbourne, Victoria, 3002, Australia
Conditions
Explore the condition pages connected to this study.